Health Care [ 10/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer.
The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer.
Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 25 | -1.32 Increased by +64.71% | -2.23 Increased by +40.81% |
| Mar 19, 25 | -1.08 Increased by +45.73% | -3.65 Increased by +70.41% |
| Nov 11, 24 | -2.55 Decreased by -390.38% | -2.10 Decreased by -21.43% |
| Aug 13, 24 | -2.29 Decreased by -1.54 K% | -2.98 Increased by +23.15% |
| May 10, 24 | -3.74 Decreased by -750.00% | -2.23 Decreased by -67.71% |
| Mar 21, 24 | -1.99 Decreased by -729.17% | -2.84 Increased by +29.93% |
| Nov 13, 23 | -0.52 Decreased by -20.93% | -0.10 Decreased by -420.00% |
| Aug 14, 23 | -0.14 Increased by +69.57% | -0.16 Increased by +12.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -28.20 M Decreased by -16.04% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -11.89 M Increased by +7.97% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -23.02 M Increased by +65.86% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -14.92 M Increased by +20.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -24.30 M Increased by +56.85% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 7.67 M Increased by +N/A% | -12.93 M Increased by +76.00% | Decreased by -168.51% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -67.43 M Decreased by -19.93% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -18.66 M Increased by +68.37% | Decreased by N/A% Decreased by N/A% |